О вас

Deca Durabolin: Uses, Benefits, And Side Effects


What is 2 O‑Methyl‑5‑Hydroxy‑1‑Phenyl (A.k.a. "2‑O‑Methyl Dianabol" or "2‑O‑Methyldianabol")?



Feature Description


Chemical name 2‑O‑methyl‑5‑hydroxy‑1‑phenyl‑3‑undecanone (a methyl ether of the hydroxyl group on the classic Dianabol).


Structure It’s a derivative of the anabolic steroid Methandrostenolone (Dianabol) where the 2‑OH is replaced by an O‑CH₃ group.


Stereochemistry The same chiral centers as Dianabol; no new stereocenters are introduced.


Pharmacology An androgenic steroid with anabolic properties; more lipophilic due to the ether, potentially improving oral bioavailability and reducing first‑pass metabolism.


---




How It Differs from Standard Steroids




Metabolic Stability


- The 2‑O‑CH₃ protects the steroid from rapid conjugation (glucuronidation or sulfation) at that position.
- This may prolong systemic circulation and increase oral potency.





Lipophilicity & Absorption


- Etherification raises logP, aiding passive diffusion across intestinal membranes.
- Oral bioavailability can be higher than for steroids with free hydroxyl groups at the same site.





Pharmacokinetics


- Reduced first‑pass hepatic metabolism often translates into a longer half‑life and fewer daily doses.



Therapeutic Profile


- A steroid with these properties could serve as a potent anti‑inflammatory or immunosuppressive agent.
- Potentially useful in conditions like rheumatoid arthritis, inflammatory bowel disease, or organ transplant rejection where long‑acting steroids are preferred.





Safety Considerations


- Enhanced potency may increase the risk of systemic side effects (e.g., hyperglycemia, osteoporosis).
- Careful dose titration and monitoring would be essential.



---



Bottom line:

A steroid bearing an O‑substituted aromatic ring is more lipophilic, better absorbed, metabolized more slowly, and therefore has a longer duration of action. Such a compound could provide strong, sustained anti‑inflammatory effects but would also require vigilant management of dose‑related adverse events.

Информация о профиле